Psoriasiform reactions during treatment with abatacept

Psoriasiform reactions during treatment with abatacept

Triggering or worsening of psoriasis has been traditionally reported in patients treated with each of the three currently available tumor necrosis factor (TNF)-α blocking agents (infliximab, etanercept and adalimumab). [2],[4],[5] In a meta-analysis of 13 relevant trials, four of 1332 RA patients w...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Indian journal of dermatology, venereology, and leprology venereology, and leprology, 2014-01, Vol.80 (1), p.92
Hauptverfasser: Conde-Montero, Elena, Baniandrés-Rodríguez, Ofelia, Mendoza-Cembranos, María Dolores, Horcajada-Reales, Celia, Suárez-Fernández, Ricardo
Format: Artikel
Sprache:eng
Schlagworte:
Abatacept
Abatacept - adverse effects
Adult
Antirheumatic Agents - adverse effects
Arthritis
Case studies
Diagnosis
Disease Progression
Drug Eruptions - etiology
Drug Eruptions - pathology
Drug therapy
Female
Health aspects
Humans
Male
Middle Aged
Patient outcomes
Psoriasis
Psoriasis - chemically induced
Psoriasis - pathology
Risk factors
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Triggering or worsening of psoriasis has been traditionally reported in patients treated with each of the three currently available tumor necrosis factor (TNF)-α blocking agents (infliximab, etanercept and adalimumab). [2],[4],[5] In a meta-analysis of 13 relevant trials, four of 1332 RA patients who received abatacept as monotherapy as well as 13 of 1945 patients treated with abatacept plus disease-modifying antirheumatic drugs developed psoriasis as an adverse event.
ISSN:0378-6323
0973-3922
1998-3611
DOI:10.4103/0378-6323.125502